May 13, 2014
1 min read

Anti-VEGFs worth the cost the government pays, SFO president says

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

PARIS — The current price of anti-VEGFs is not too high, considering the benefits they provide, according to Jean-François Korobelnik, MD, president of the French Society of Ophthalmology.

Jean-François Korobelnik

“The media have put a lot of emphasis on the cost of anti-VEGFs. But we are investing on expensive treatments also for cancer to prolong life of a few months, and new promising molecules for hepatitis C are going to cost €60,000 for 3 months of therapy,” he said.

The French Ministry of Health, which provides full reimbursement for approved anti-VEGF therapies, spent in 2013 €429 million for Lucentis (ranibizumab, Genentech/Novartis) — the No. 1 investment for drug coverage last year — and €12 million in 3 months for Eylea (aflibercept, Regeneron/Bayer). This financial burden is expected to grow with increasing demand for treatment in future years.

“The government might be able to negotiate with manufacturers a lower price for Lucentis after 7 to 8 years of utilization, with Eylea getting into the scene and following approval of Lucentis for more indications,” Korobelnik said. “Ideally, there should be a European price or even a world price.”

He did not express favor of government provisions that may allow the off-label use and reimbursement of Avastin (bevacizumab, Genentech/Roche). The additional costs related to compounding, storage, traceability and treatment of epidemic infections due to contamination might, in fact, make the final price less remarkable, he said.

Disclosure: Korobelnik is a consultant to BayerNovartis and Roche.